top of page
Nov 12, 20191 min read

Skyhawk’s $80M Celgene deal expands remit to autoimmune


In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for autoimmune disease and cancer against hard-to-drug targets that have been clinically validated, or genetically associated with a disease.



For more information visit:


SKYHAWK MEDIA CONTACT:

Maura McCarthy




Comments

bottom of page